FDA approves Novartis Pluvicto for earlier-stage prostate cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| NOVARTIS AG (NYSE: NVS) | Delayed: 156.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $156.27 | 52 Week High | $89.15 | |||
| Open | $156.27 | 52 Week Low | $69.84 | |||
| Day High | $156.27 | P/E | N/A | |||
| Day Low | $156.27 | EPS | $0.00 | |||
| Volume | 10,961 | |||||
